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Abstract
Hormonal contraception is central in the prevention of unintended pregnancy; however there are 
concerns that certain methods may increase the risk of HIV acquisition and transmission. 
Hormonal contraceptives may modify the genital mucosa in several ways, however the 
mechanisms are incompletely understood. Few studies have examined genital HIV shedding 
prospectively before and after initiation of hormonal contraception. The effects of hormonal 
contraception on genital HIV shedding in the setting of antiretroviral therapy (ART) are also 
unknown. We designed a pilot clinical trial in which HIV-infected and uninfected women were 
randomized to either depot medroxyprogesterone acetate (DMPA) injectable or levonorgestrel 
(LNG) implant in Lilongwe, Malawi. The objectives were to: 1) assess the effect and compare the 
impact of type of progestin contraception (injectable versus implant) on HIV genital shedding 
among HIV-infected women, 2) assess the effect and compare the impact of type of progestin 
contraception on inflammatory/immune markers in the genital tract of both HIV-infected and 
uninfected women, and 3) assess the interaction of progestin contraception and ART by examining 
contraceptive efficacy and ART efficacy. An additional study aim was to determine the feasibility 
and need for a larger study of determinants of HIV transmissibility and acquisition.
As injectable contraception is widely used in many parts of the world with high HIV prevalence, 
this study will provide important information in determining the need for and feasibility of a larger 
study to address these questions that can impact the lives of millions of women living with or at 
risk for HIV.
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1. Introduction
Globally, over 35 million people are living with HIV, including 16 million women [1]. Like 
most women, HIV-infected women are in need of safe and effective contraceptive methods. 
There are many benefits to preventing unintended pregnancy among women. Unintended 
pregnancy is associated with increased morbidity and mortality, and in HIV-infected women 
it can prevent the birth of children at risk for HIV transmission. Globally, the most common 
forms of modern contraception used are progestin-containing hormonal contraceptive 
methods, either alone or in combination with estrogen, with over 150 million users around 
the world [2].
Despite its contraceptive benefits, there are concerns that certain types of hormonal 
contraception may increase the risk of HIV acquisition and transmission. Recent systematic 
reviews on the role of contraceptives in HIV acquisition [3] and female-to-male transmission 
[4] concluded that the preponderance of data suggest that oral contraceptives do not increase 
risk and that, while studies are limited, there is also no evidence of an increased risk with 
contraceptive implants. In contrast, the results are less consistent with injectable 
contraceptives. Of the nine studies on injectable contraception and HIV acquisition 
considered of adequate quality [3], four reported a significant increase in risk of HIV 
acquisition with injectables [5–8]. Among HIV-infected women, the only study of adequate 
quality [4] that assessed the risk of female-to-male transmission with injectable 
contraception found an increased risk [5]. Furthermore, of the three studies evaluating the 
role of injectables on genital shedding of HIV-1 DNA and RNA, all found increased cervical 
shedding with injectables [5,9,10]. Although these findings have potentially serious public 
health and policy implications, the inconsistency among studies and methodologic 
weaknesses limit interpretation [11]. A World Health Organization (WHO) consultation 
concluded that there was as yet insufficient evidence to support a change in the current 
guidelines of no restriction on the use of progestin-only injectable contraceptives among 
women at high risk for HIV acquisition or among HIV-infected women [12]. However, the 
WHO states that women at high risk of HIV acquisition considering progestin-only 
injectables should be informed about the uncertainty of whether or not injectables increase 
acquisition risk and be provided access to HIV preventive measures, including male and 
female condoms.
Since access to ART is increasing worldwide, there is also a need to evaluate the impact of 
hormonal contraception on HIV transmissibility among HIV-infected women on ART, an 
area with a paucity of data. Pharmacokinetic data suggest potential drug interactions 
between some antiretrovirals and hormonal contraceptives. Currently, the WHO only 
restricts contraceptive pill, ring and implant use with specific antiretroviral regimens [13]. 
DMPA is listed as category 1 (no restrictions to use) with the three major classes of 
antiretrovirals: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse 
transcriptase inhibitors (NNRTI), and protease inhibitors (PI). However, LNG is listed as 
category 2 (benefits of use outweigh the theoretical or proven risks) when NNRTI or 
ritonavir-boosted PI are used [13].
Kourtis et al. Page 2
Contemp Clin Trials. Author manuscript; available in PMC 2017 June 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2. Rationale for the study
The knowledge/understanding of the mechanism by which hormonal contraception may 
modify sexually transmitted infection (STI) and HIV risk is incomplete. Hormonal 
contraception may work systemically or locally within the genital tract to alter HIV 
susceptibility and transmissibility [14–32]. The physiology, cell composition, and 
immunology of the genital tract, a critical portal for HIV entry and source of transmission to 
partners and to newborns during childbirth, can be altered by changes in endogenous 
hormones and hormonal contraception. Changes in gonadal hormonal levels may alter 
vaginal wall thickness or barrier function [33], vaginal pH, vaginal microbiome [34], 
cervical cell ectopy [35], cervical mucus [36], and susceptibility to STIs [37–41].
DMPA leads to high levels of systemic progestin concentrations with profound suppression 
of endogenous estrogen. This high-progestin, low-estrogen state may affect HIV 
susceptibility. Estradiol and progesterone regulate multiple functions in the genital tract, 
including homing of immune cells, chemokines and cytokines, [42] mucosal cellular 
composition, [43–45] and epithelial cell receptor expression [46]. Progesterone and its 
derivatives can increase infiltration of antigen-presenting cells in the vaginal epithelium, as 
well as CD4 + CCR5+ lymphocytes and CD8+ T-lymphocytes in genital tract tissues 
[44,47–54]. Estrogen, on the other hand, has been shown to decrease recruitment of 
activated T-cells and macrophages [55]. Thus, it appears that progesterone might increase, 
while estrogen may decrease, the frequency of HIV-1 target cells in the female genital tract.
Another potential pathway by which hormonal contraception may affect HIV infectivity is 
by increasing the prevalence of other genital infections. DMPA use has been associated with 
decreased H2O2-positive Lactobacillus and increased acquisition of cervical chlamydial and 
gonococcal infections, herpes simplex 2 infection, and candidiasis in women 
[31,35,45,56,57]. Presence of other genital tract infections has been associated with 
increased genital tract HIV shedding and HIV transmission [58–60]. While some studies 
have suggested that DMPA does not alter the prevalence of bacterial vaginosis or vaginal 
candidiasis, the impact on the vaginal microbiome utilizing more sensitive genetic 
sequencing techniques is not well characterized [56,61–66].
There are several different injectable hormonal contraceptives, but DMPA via the IM 
formulation (150 mg IM) is by far the most commonly used globally. A factor limiting 
contraceptive effectiveness is poor adherence to the repeated injections (every 3 months). 
Efforts have been made to promote longer-term contraceptive options, such as contraceptive 
implants. There have been several contraceptive implants utilized globally, including Jadelle, 
Implanon, Nexplanon, Norplant and Sino-implant. Jadelle, a 2 rod-implant, with each rod 
containing 75 mg of levonorgestrel (LNG), is the most commonly used in Africa with an 
efficacy for up to 5, and possibly 7, years [67] following insertion. Given the increasing 
acceptance of LNG implant use in regions with high HIV prevalence [68], its high efficacy 
in preventing unintended pregnancy, and its longer duration of action, we chose to use the 
Jadelle LNG implant as the comparison method in this study.
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Different progestins could have different effects on the immune system and the genital tract 
due to variations in dose, methods of absorption, metabolism, pharmacokinetics, 
bioavailability, and/or binding of serum proteins and enzymes. Different progestin-only 
methods will also differ with regards to peak serum progestin concentrations, as well as 
varying degrees of hypothalamic-pituitary-ovarian axis modulation with resultant 
suppression of estrogen. Currently available progestins include a wide range of 
progestogenic molecules with variable degrees of estrogenic, androgenic, anti-androgenic, 
glucocorticoid and anti-mineralocorticoid activity [69]. Medroxyprogesterone (MPA), for 
example, has potent glucocorticoid activity, higher than any other progestin or endogenous 
progesterone, and this could theoretically enhance susceptibility to HIV. The effects of 
different progestins on the genital tract and relative impact on HIV viral shedding may thus 
be different, but have yet to be explored [70]. Among progestin-only methods, DMPA 
concentrations will quickly increase after intramuscular injection, with the highest levels 
occurring within the first month followed by a plateau of serum concentrations at 1.0–1.5 
ng/mL for about 3 months, after which blood levels decline slowly. Endogenous estradiol 
levels and progesterone levels are suppressed for several months after DMPA injection 
corresponding to suppression of ovulation [71]. Study findings suggest an antiprogestogenic 
effect on the vaginal mucosa with MPA that may not be shared by other contraceptives [70].
For the levonorgestrel implant, release of levonorgestrel is sufficient to prevent pregnancy 
within 24 h of insertion, reaching a maximum level 2 days after placement, with release of 
100 μg/day of levonorgestrel during the first month, declining to about 40 μg/day at 12 
months and stabilizing at 30 μg/day at 24 months and thereafter. Serum concentrations may 
vary by metabolic clearance rate, body weight and other factors, but they are not necessarily 
predictive of pregnancy risk. Serum estrogen concentrations are significantly lower with 
DMPA compared to LNG implant users [70]. Tissue-specific and systemic effects of the 
LNG implant are poorly characterized.
Although the mechanisms of action, kinetics of hormone release, and impact on endogenous 
hormonal concentrations differ between different forms of progestin-releasing 
contraceptives, studies examining the effects of these methods on HIV transmission are 
limited. To our knowledge, there is only one study that examined HIV RNA shedding among 
5 women using Norplant [10] and no studies that have evaluated Jadelle or Sino-implant. 
This was another knowledge gap we sought to fill with this study.
In 2012, the Centers for Disease Control and Prevention (CDC) and the University of North 
Carolina at Chapel Hill (UNC) began designing a randomized controlled trial to fill in these 
knowledge gaps by evaluating the effect of two different progestin contraceptive methods on 
HIV genital shedding among HIV-infected women and on the inflammatory/immune/
microbial changes in the genital tract of HIV-infected and uninfected women. This paper 
describes the process of designing the study protocol, as well as the evolution of this 
protocol to reflect changes that were implemented in light of new emerging knowledge 
leading to evolving research priorities in a rapidly moving field.
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3. Methods
3.1. Study objectives
To address the study aims we specified the following objectives: 1. To assess the effect and 
compare the impact of type of progestin contraception (injectable versus implant) on HIV 
viral shedding in the genital tract of HIV-infected women; 2. To assess the effect and 
compare the impact of type of progestin contraception (injectable versus implant) on 
inflammatory/immune markers in the genital tract of both HIV-infected and HIV-uninfected 
women; 3. To assess the interaction of progestin hormonal contraception and ART by 
examining: i. contraceptive efficacy (measured by systemic hormone levels and pregnancy 
rate during follow-up) and ii. ART efficacy (by drug concentrations in blood and genital 
tract and HIV viral load response in the plasma in women on ART).
3.2. Study design
This study was a randomized trial of the effect of progestin contraception on HIV shedding 
and mucosal immune activation in the genital tract. HIV shedding and other study outcomes 
were evaluated by: 1) a within-subject assessment comparing the time periods before and 
after randomization to a progestin contraceptive, 2) an across-study arms comparison of the 
difference between the study interventions (DMPA and LNG implant), and 3) an across-
study arm comparison of immune genital tract changes between HIV-infected and HIV-
uninfected women using progestin contraception. Antiretroviral use was evaluated for an 
independent effect on HIV shedding and also to determine if it modified the effects of 
menstrual cycle or progestin contraception on HIV shedding. To analyze the effects of 
progestin contraception on genital inflammatory/immune markers, HIV-infected and 
uninfected women on progestin contraception were compared separately and combined, with 
HIV status treated as a potential effect modifier, within each study arm (before and after 
initiation of contraception), as well as between the two contraceptive arms.
The study aimed for potential subjects to be screened for entry until 100 HIV-infected and 
30 HIV-uninfected women were recruited and randomized to receive either DMPA injections 
(n = 50 HIV-positive, 15 HIV-negative) or the LNG implant (n = 50 HIV-positive, 15 HIV-
negative). HIV-infected women may or may not have been on ART to treat their HIV 
infection. Evaluation was conducted in two stages: the pre-intervention stage to assess 
baseline status by stage of menstrual cycle; and the intervention stage where the variables of 
interest were measured while on the contraceptive intervention.
3.3. Study population, location and personnel
The study took place at Bwaila Maternity Hospital in Lilongwe, Malawi. With a population 
of approximately 16.3 million people, Malawi has a per capita income of $750 and per 
capita total expenditure on health of $91 ($ amounts are Purchasing Power estimates by 
WHO at the international $ rate) [59]. The estimated HIV prevalence among adults ages 15–
49y is 10.8% [1]. Forty-two percent of all married women use contraception, and there is a 
26% unmet need for family planning [72].
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Since 1990, UNC has been working in Malawi with local partners conducting research with 
activities centered in Lilongwe. Bwaila Maternity Hospital was also the site of the CDC-
sponsored Breastfeeding, Antiretrovirals, and Nutrition (BAN) clinical trial [73].The CDC 
institutional review board (IRB), the UNC IRB, the Malawi National Health Sciences 
Research Committee, and the Malawi Pharmacy, Medicines & Poisons Board approved the 
initial protocol and all amendments prior to implementation.
The participants for this study were recruited from clinic patients at Bwaila Maternity 
Hospital (Bwaila) Family Health Unit and from other clinics based at the Bwaila Maternity 
Hospital and in the surrounding area. Public radio announcements about the study were also 
broadcast during the first two weeks of study enrollment.
Women who desired to start hormonal contraception were informed of the study and 
counseled on the progestin contraceptives available within the study. Eligible women who 
provided informed consent and agreed to randomization to either DMPA or the LNG implant 
were enrolled. To address the primary outcomes of HIV shedding and mucosal immune 
activation, we quantified genital tract HIV DNA/RNA and inflammatory/immune markers 
(cytokines/chemokines, activation markers) at two time points before and several time points 
after randomization of the HIV-infected and HIV-uninfected women to DMPA or LNG 
implant. The two time points prior to randomization were chosen within the prior menstrual 
cycle, with one visit in the follicular phase and the other visit in the luteal phase of the cycle. 
Assessments after initiation of contraception occurred on days 3, 30, 90, 6 months, and 
every 3 months thereafter until a follow-up time of up to approximately 2 years and 9 
months was completed. Antiretroviral concentrations in the blood and genital tract were also 
assessed at these time points.
3.4. Sample size
HIV-infected women were enrolled to address the primary objective of comparing genital 
tract HIV shedding using DMPA injections or LNG implants. The sample size of 100 was 
primarily chosen for this pilot trial because of logistical considerations, in part to evaluate 
the feasibility of randomization to two different contraceptive methods, and in part to 
determine whether a larger trial would be feasible and/or necessary. Based on our statistical 
methods described below, a sample size of 100 women is sufficient to detect a 0.5 log10 
difference in viral shedding before and after initiation of progestin contraception, a 
difference that is clinically meaningful, as each log10 increase in HIV genital shedding has 
been estimated to lead to an approximate two-fold increase in transmission risk [95]. Based 
on previous studies [74,75], we also determined that a sample size of 30 HIV-uninfected 
women would be sufficient to explore differences in distributions of several different 
immunologic markers in women randomized to DMPA and LNG implant.
3.5. Statistical considerations
For the first primary study objective, we hypothesized that there will be an increase in the 
magnitude of genital HIV shedding following initiation of progestin contraception. There 
was no information on the direct comparability of genital HIV shedding with DMPA and 
LNG implant and if the shedding would be more or less notable for HIV RNA or DNA.
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The difference in HIV shedding before and after starting progestin contraception in this trial 
depends on the magnitude of genital HIV detection before starting progestin contraception, 
the assumed correlation coefficient between a participant’s repeated measurements at 
follow-up visits, the Type I error rate, and the power to detect a statistically significant 
effect. Data from studies of HIV RNA cervical shedding of women not on ART [76–78], as 
well as women on ART [10,79–81], formed the basis for estimating this detectable 
difference in genital HIV shedding in this study given our sample size of 100 HIV-infected 
women. We estimated that approximately one third of our HIV-infected (n = 33) study 
population would not be on ART yet due to their CD4+ T cell count (following criteria for 
treatment initiation at the time), while two thirds (n = 67) would be on ART. Assuming a 
mean 2.0 log10 cervical HIV RNA level prior to initiation of contraception in our study [10, 
78], we would be able to detect a 0.51 log10 difference after initiation of progestin-based 
contraception with a power of 80%, alpha = 0.05, a 10% loss-to-follow-up rate, and a 
within-subject correlation coefficient of 0.20. We would also be able to detect a 0.50 log10 
difference in viral shedding between the LNG-implant arm and the DMPA arm after 
initiation of contraception.
3.6. Recruitment, screening, and enrollment
The study recruited women who expressed an interest after hearing a brief overview of the 
study and its eligibility criteria. Interested women received comprehensive family planning 
education from a Study Nurse using the Malawi Ministry of Health’s family planning 
counseling flipbook, known as “Kulera” that reviews all available family planning methods 
in Malawi and includes information on both DMPA and the implant.
Women who after completion of this education session were still interested in the study and 
who provided informed consent for screening procedures were screened to determine 
eligibility. The inclusion criteria were: 1) females aged 18–45 years; 2) known HIV status, 
as documented by at least two concordant rapid tests; 3) at least two regular, monthly cycles 
(~21–35 days) in the three months preceding study enrollment; 4) off hormonal or 
intrauterine contraception for at least 6 months (if previously using DMPA, last injection 
must have been ≥6 months ago); 5) at least 6 months postpartum; 6) interested in initiating a 
family planning method, specifically DMPA or the LNG implant; 7) willing to be 
randomized to receive either DMPA or the LNG implant; 8) willing to wait 4–6 weeks after 
enrollment to receive the method and to use non-hormonal and non-intrauterine methods 
(such as abstinence or condoms) consistently during this period.
Exclusion criteria were: 1) pregnancy (by clinical history or a positive urine test at 
screening); 2) current use of any hormonal contraception method; 3) desire to become 
pregnant within the next 12 months; 4) untreated visible genital ulcers or lesions on initial 
pelvic examination; 5) known or suspected genital tract cancer (by clinical history or noted 
during initial pelvic examination); 6) any contraindications to DMPA or LNG implant per 
the WHO medical eligibility criteria [82] or judgment of clinician (contraindications include 
lactation within first 6 weeks postpartum, acute deep venous thrombosis or pulmonary 
embolism, lupus, migraine with aura, unexplained vaginal bleeding, current or history of 
breast cancer, severe cirrhosis, liver tumors, history of stroke, current or history of ischemic 
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heart disease); 7) acute HIV infection (as documented by a known negative HIV test 6 
months or less prior to screening).
Women who met all eligibility criteria and were good candidates for study participation 
based on the assessment of the site investigator or designee were enrolled into the study after 
providing informed consent for enrollment.
4. Schedule of study visits
Enrolled women were followed for two study visits during the month preceding 
randomization; after randomization, women were followed for up to two and a half years. 
The schedule of the visits was designed to collect samples from both the follicular and luteal 
phases in the menstrual cycle prior to contraceptive intervention and to coincide with key 
times in the progestin concentration pharmacokinetic curve for those on DMPA (peak, 
decreasing, trough), as well as the time of repeat injections (every 3 months) (Tables 1 and 
2). For comparability, participants on the implant arm were followed at the same time points. 
Both history and hormonal assessment were used to confirm phase of menstrual cycle. If a 
participant was experiencing menstrual bleeding during a follow-up visit, pelvic evaluations 
were deferred until after menses were complete.
At the enrollment visit, a detailed assessment including questions about demographic, 
medical, gynecologic and sexual history was conducted. At each follow-up visit an interval 
history assessment and physical exam were conducted. Specimen collection included blood 
and genital samples (Tables 1 and 2). Condoms were provided to all participants at each visit 
as well as contraceptive and HIV/STI risk-reduction counseling.
Specimens collected at follow-up visits were tested for rapid plasma reagin (RPR) (with 
confirmatory Treponema Pallidum Hemagglutination Assay testing if positive), Herpes 
Simplex Virus-type 2 (HSV-2), Chlamydia trachomatis, Neisseria gonorrhoeae, and 
Trichomonas vaginalis. Testing was conducted because sexually transmitted infections could 
cause inflammatory genital tract changes, which are potential confounders for the HIV viral 
shedding and inflammatory/immune markers outcomes and will be accounted for in 
analyses.
In HIV-infected women, Tear-Flo strips were used to collect cervicovaginal fluid for HIV-1 
RNA quantitation and Weck-Cel sponges were used to collect cervicovaginal secretions for 
ART drug level testing (if the woman was on ART). Concentrations of the antiretroviral 
agents were measured in the plasma and the upper layer of packed cells (ULPC) [83].
For both HIV-infected and HIV-uninfected women, a cervicovaginal lavage (CVL) sample 
was collected. The fluid portion was used for testing of immune markers, and centrifuged 
cell pellets were tested for HIV proviral DNA in HIV-infected women.
The genital tract HIV-1 DNA and RNA levels obtained from CVL were compared to the 
HIV-1 RNA levels obtained by cervical Tear-Flo strips. There are advantages and 
disadvantages to assessing HIV concentrations with each specimen type (CVL vs. Tear-Flo). 
The use of progestin is expected to induce changes in the thickness and other characteristics 
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of cervical mucus, which has the theoretical potential to affect viral concentrations. On the 
other hand, the effect of dilution of mixed cervicovaginal secretions by the method of 
obtaining CVL may also affect ability to detect virus in the genital tract more so than direct 
collection. For these reasons a direct comparison of CVL vs. Tear-Flo was performed, thus 
advancing the field methodologically. In addition, both HIV RNA and proviral DNA were 
evaluated in this study, given lack of consensus about the relative contribution of cell-free vs. 
cell-associated virus in transmission risk [84].
For HIV-negative women only, a cervical cytobrush specimen for cellular immune activation 
testing was collected after the CVL collection. In addition, for HIV-negative women, blood 
was also collected to evaluate for cellular activation of the same markers in whole blood.
For all women, blood was collected for hormonal assessment (estradiol, progesterone, 
medroxyprogesterone, or LNG were also assessed as appropriate). In HIV-infected subjects, 
blood was obtained to test for CD4+ T cell count, HIV RNA viral levels, HIV resistance 
mutations and antiretroviral concentrations.
5. Provisions for protecting privacy and confidentiality
Participants’ privacy and the confidentiality were protected through formal training of 
interviewers and other study staff in good clinical practices, study ethics, human subjects 
research and protocol procedures. All interviews and physical examinations were conducted 
in private, and all study materials were stored in a locked room. Only a coded study 
participant identification number (PID) was used on study documents containing participant 
data. Participants’ names were stored separately from documents containing participant data 
in a locked file in a locked office. Linkages between PIDs and participants’ identifying 
information were maintained on a paper log kept locked and only accessible to limited on-
site study staff.
6. Protocol amendments
Since study initiation, some new information became available, as some studies suggested 
there might be an interaction of ART and progestin implants resulting in reduced 
contraceptive effectiveness: A literature review [85] noted a few case reports of women on 
ART regimens who conceived pregnancies while on Implanon® (etonorgestrel implant) after 
24 months of use. A retrospective chart review suggested that efavirenz (EFV) may decrease 
the efficacy of LNG implants [86]. The mean time between implant insertion and pregnancy 
was 16.4 months for the women who became pregnant in that study [86]. Results from a 
pharmacokinetic study suggested that LNG levels in 20 women receiving EFV were lower 
compared with women not on EFV [87]. Updated results from this small prospective cohort 
study showed that 3 women on EFV became pregnant between 36 and 48 weeks after LNG 
implant insertion, compared to none in the control group [88]. Two of the pregnant women 
had LNG levels >180 pg/mL at their prior visit, which had previously been thought to be the 
minimum drug concentration needed to prevent pregnancy. While additional prospective 
studies are needed to assess the clinical significance (actual increase in pregnancies due to 
decreased hormonal levels) among HIV-infected women taking EFV [89], these findings 
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raised concern about use of LNG implants in women taking EFV. In 2014, USAID provided 
guidance for counseling women who are on ART and progestin implants, taking into 
account the limited information available [89].
Given this new concern, a protocol amendment was implemented in December 2014 to 
provide additional counseling regarding the possible decreased effectiveness of implants in 
preventing pregnancies for women on EFV. Prior to screening, all potential participants were 
provided with this additional counseling in conjunction with the standard family planning 
counseling. For those women already enrolled into the study, counseling was provided to all 
HIV-infected participants not yet randomized to a contraceptive method and to all HIV-
infected participants randomized to the LNG implant arm. Two subsequent amendments 
were implemented to increase the amount of follow-up time from 6 months post-
contraceptive initiation to up to about 2 years and 9 months post-contraceptive initiation, in 
order to evaluate the frequency of occurrence of breakthrough pregnancies; and to obtain 
qualitative data on women’s understanding of the counseling messages and reasons for 
continuing or discontinuing their contraceptive methods longer-term. The testing schedule 
was simplified after the initial 6 month period to only cervical swabs for HIV RNA to 
evaluate genital shedding and no further cytobrush specimens in the HIV-uninfected women.
7. Current status
Recruitment and retention in the study has been robust and randomization to a contraceptive 
method was acceptable and feasible. Of the 97 women randomized to a contraceptive 
method, 96 have already completed 6 months of follow-up and extended follow-up is 
ongoing.
8. Discussion
The study seeks to address several knowledge gaps that affect HIV-infected and HIV-
uninfected women in resource-limited and resource-rich settings: the safety of hormonal 
contraception with regard to HIV acquisition and transmission, as well as the effectiveness 
of certain forms of progestin contraception when given in conjunction with some ART 
agents. Progestin contraception is particularly important to study for several reasons. First, 
due to the lack of pharmacokinetic interactions with ART, DMPA is widely used among 
HIV-infected women on ART in many settings, including resource-limited settings with high 
HIV prevalence. Second, these forms of contraception do not require daily administration 
(e.g. pills) or per-coital act (e.g., condoms) adherence, and are thus more effective in 
preventing pregnancy. Promotion of longer-acting reversible contraceptive (LARC) methods, 
such as the implant, is particularly desirable, due to their high effectiveness and less reliance 
on the woman’s memory and adherence. This study will be able to examine the effects of 
these forms of contraception on genital HIV shedding (both RNA and DNA) and on immune 
markers, compare genital HIV shedding and immune markers before and after initiating 
contraception among HIV-infected and uninfected women, and also compare the two forms 
of contraception in a randomized design.
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Plasma viral load has been shown to be a very strong predictor of heterosexual transmission 
[79,80], and ART effectively decreases viral load in the blood and in the genital tract [90]. 
However, several reports have documented that HIV-1 may remain present in the 
cervicovaginal fluid of patients on ART even if the individual has undetectable plasma viral 
load [13,80,91–93]. Furthermore, although transmission is markedly reduced by ART, it 
does not appear to be completely eliminated [84,94–97], as low-level viral replication may 
persist within the genital tract, even with undetectable plasma viral load. Studies of women 
on ART have found cervical HIV RNA detectable in 3% to 33% of women studied 
[10,79,80,98], depending on whether the woman has undetectable plasma viral load (VL) or 
not [10]. Median genital viral load has been estimated to decrease by about 2 log by 6 
months after initiation of ART (from 4.0 to 1.7 log) [10]. It is thus important to address 
potential modulating factors that can alter genital viral loads in the setting of ART [99,100].
From studies among ART-naïve populations, genital tract HIV RNA load correlates 
significantly but imperfectly with plasma viral load level (r = 0.56) [77,101–103]. Genital 
HIV RNA has been shown to be an independent risk factor for heterosexual HIV 
transmission, even after adjustment for plasma viral load, with each 1 log increase in 
cervical HIV RNA levels associated with a 2.2-fold increased risk of transmission to the 
male partner (adjusted hazard ratio of 1.67 after adjustment for plasma viral load) [101]. 
Genital tract HIV shedding can be intermittent and may be upregulated by pregnancy, HSV 
reactivation, alterations in vaginal flora, time in the menstrual cycle, and even nutritional 
deficiencies [104–106]. Thus, measurement of genital HIV quantity is a strong surrogate 
marker of HIV transmission risk, suggesting that the potential impact of new interventions 
aimed at reducing HIV transmission can be assessed through studies of genital HIV RNA 
[101].
As mentioned, prior studies have evaluated the impact of hormonal contraception on HIV 
genital tract shedding, but results are contradictory about DNA or RNA shedding; studies 
have also used different genital specimens, resulting in difficulty of interpreting or 
generalizing the information. Our study offers the methodologic advantage of using outcome 
measures of both HIV RNA and DNA from two genital specimen types (cervicovaginal 
lavage and cervical swab), obtained at the same time from each woman, at several time 
points before and after initiation contraception, at times to coincide with different phases of 
the menstrual cycle, as well as critical points to construct pharmacokinetic curves of 
progestin concentrations. Also, this is the first study to compare different progestins in a 
randomized fashion, thus circumventing the potential problem of confounding associated 
with self-selection of contraceptive method, as well as recall bias when based on self-
reported contraceptive use.
The results of our study will add to the evidence base regarding the comparative safety of 
two different progestin contraceptives for women with and at-risk for HIV and the 
effectiveness of progestin implants with concomitant use of EFV. This study will add to the 
understanding of immunologic and genital tract changes that occur with progestin-only 
contraception and how these changes may relate to risk of HIV acquisition among HIV-
uninfected women. In addition, prospective information on risk of contraceptive failure of 
LNG implants with concurrent use of EFV that can aid in formulating evidence-based 
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recommendations for hormonal contraceptive use among women on ART. Finally, this study 
will help increase local state-of-the art clinical research and laboratory capacity at the study 
site. Based on the findings of this study and the size of the effects observed, the need for a 
larger study to obtain a more definitive answer to these questions will be determined.
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